Infection News

CHICAGO — During this year’s North American Society for Pediatric Gastroenterology, Hepatology & Nutrition annual meeting, Mercedes Martinez, MD, from the New York-Presbyterian Columbia University Irving Medical Center in New York, will co-host the Single Topic Symposium on Chronic Liver Disease Management for the Gastroenterologist.

In contrast to previous study results, hepatocellular carcinoma and decompensated cirrhosis rates were similar between patients coinfected with hepatitis C and HIV and those with hepatitis C alone, according to data.

Compared with standard of care, fecal microbiota transplantation decreases mortality among patients with severe and fulminant Clostridioides difficile infection, according to study results.

The rates of hepatitis C infection at delivery among pregnant women in the U.S. increased between 2000 and 2015, especially among women with concomitant opioid use disorder, the prevalence of which also increased during that period.

Results from a real-world study of implementing hepatitis C testing into integrated care centers that deliver HIV services to people who inject drugs demonstrated superior infection awareness, testing and treatment compared with usual care.

Experts on fecal microbiota transplantation from Europe, North America and Australia have released a new consensus report that provides guidance on how to establish, operate and regulate stool banks.

WASHINGTON — The investigational microbiota-based drug, RBX2660, safely and effectively prevented recurrent Clostridioides difficile infection, or rCDI, and demonstrated clinical durability 2 years after treatment, according to findings from the PUNCH open-label study presented at IDWeek.

With several highly effective, curative direct-acting antiviral options for patients with hepatitis C, the focus has changed from management of the viral infection to a march toward global elimination.

SAN ANTONIO — Healio will host its second Disruptive Innovators reception during the American College of Gastroenterology’s Annual Scientific Meeting (ACG 2019) on October 27, 2019, at the Grand Hyatt San Antonio.

The FDA accepted a new drug application for the oral suspension formulation of Dificid, Merck’s macrolide antibiotic. At the same time, it accepted a supplemental new drug application for the drug in tablet and oral suspension form for the treatment of Clostridioides difficile infection in children aged 6 months or older, Merck announced.